Skip to main content

Cutaneous Phosphorylated α-Synuclein Frequently ID'd in Synucleinopathies

Medically reviewed by Carmen Pope, BPharm. Last updated on March 25, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, March 25, 2024 -- A high proportion of individuals with synucleinopathies has positivity for cutaneous phosphorylated α-synuclein, according to a study published online March 20 in the Journal of the American Medical Association.

Christopher H. Gibbons, M.D., from Harvard Medical School in Boston, and colleagues examined the positivity rate of cutaneous α-synuclein deposition in patients with Parkinson disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and pure autonomic failure (PAF) in a study conducted at 30 sites. Patients aged 40 to 99 years with a clinical diagnosis of PD, DLB, MSA, or PAF and control participants aged 40 to 99 years with no history of examination findings or symptoms suggestive of a synucleinopathy or neurodegenerative disease were included (223 and 120 individuals, respectively).

The researchers found that the proportions of patients with cutaneous phosphorylated α-synuclein detected by skin biopsy were 92.7, 98.2, 96.0, and 100 percent with PD, MSA, DLB, and PAF, respectively, compared with 3.3 percent of controls.

"Further research is needed in unselected clinical populations to externally validate the findings and fully characterize the potential role of skin biopsy detection of phosphorylated α-synuclein in clinical care," the authors write.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted March 2024

Read this next

Odds of Death Lower With Surgery for Hip Fracture in Patients With Dementia

MONDAY, June 3, 2024 -- For community-dwelling patients with dementia and fracture of the femoral head and neck, the odds of death are lower for those treated surgically...

Preeclampsia Linked to Increased Risk for Young-Onset Dementia

FRIDAY, May 31, 2024 -- Individuals with preeclampsia have an increased risk for young-onset dementia, according to a research letter published online May 30 in JAMA Network...

Self-, Partner-Reported Cognitive Decline Linked to Tau

THURSDAY, May 30, 2024 -- Individuals who self-report and whose partners report cognitive decline have greater tau, which is driven by elevated beta-amyloid (Aβ), according...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.